New Product Increases T-Cell Count in HIV/AIDS Patients
CLAREMORE, OK-Ives Health Company has released a brief summary of the touted Java project.
The project was a landmark AIDS study carried out by Slayton-Beedeen, MD, an immunologist and founder of the product T-Factor. Slayton-Beedeed worked with the World Health Organization (WHO) in Jakarta and Bangkok, testing HIV positive patients of Asian descent with elevated HIV RNA and decreased CD-4 counts. They administered T-Factor and found that new hormonal inhibitors of HIV might initiate profound suppression of HIV replication.
They gave these HIV-positive patients the drug and found 80% experienced documented decreases in HIV RNA and enhanced CD-4 counts within 24 weeks.
T-Factor costs less than $3 per day, in comparison to other HIV drug therapies that cost an estimated $80 daily.
New studies of the product are taking place in the US and in Europe.
For more information about the company or T-Factor, visit www.iveshelath.com.
Show, Tell, Teach: Elevating EVS Training Through Cognitive Science and Performance Coaching
April 25th 2025Training EVS workers for hygiene excellence demands more than manuals—it requires active engagement, motor skills coaching, and teach-back techniques to reduce HAIs and improve patient outcomes.
The Rise of Disposable Products in Health Care Cleaning and Linens
April 25th 2025Health care-associated infections are driving a shift toward disposable microfiber cloths, mop pads, and curtains—offering infection prevention, regulatory compliance, and operational efficiency in one-time-use solutions.
Phage Therapy’s Future: Tackling Antimicrobial Resistance With Precision Viruses
April 24th 2025Bacteriophage therapy presents a promising alternative to antibiotics, especially as antimicrobial resistance continues to increase. Dr. Ran Nir-Paz discusses its potential, challenges, and future applications in this technology.
Robust infectious disease surveillance, including rapid subtyping of influenza A, is essential for early detection, containment, and public health reporting of novel viral threats.
